Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.
Authors
- Francisco Vega (ORCID: https://orcid.org/0000-0001-5956-452X)
- Kumudha Balakrishnan (ORCID: https://orcid.org/0000-0001-6249-2811)
- Sushanth Gouni (ORCID: https://orcid.org/0000-0001-5183-2251)
- Faezeh Darbaniyan (ORCID: https://orcid.org/0009-0000-5684-7786)
- Federico Mario Aletti (ORCID: https://orcid.org/0000-0003-1472-837X)
- Selin Kolsuz (ORCID: https://orcid.org/0000-0002-9067-9939)
- M R Green (ORCID: https://orcid.org/0000-0001-6309-9472)
- Karan L. Chohan (ORCID: https://orcid.org/0000-0003-1239-074X)
- Sridevi Patchva
- Sattva Swarup Neelapu (ORCID: https://orcid.org/0000-0003-1045-4914)
- Mario Luiz Marques-Piubelli (ORCID: https://orcid.org/0000-0002-6324-2096)
- Luisa M. Solis Soto (ORCID: https://orcid.org/0000-0002-1253-630X)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Fuliang Chu (ORCID: https://orcid.org/0000-0002-1664-5386)
- Swami Iyer (ORCID: https://orcid.org/0000-0003-4375-5844)
- Jingwei Liu (ORCID: https://orcid.org/0000-0003-4943-3926)
- Wei Lü (ORCID: https://orcid.org/0000-0003-4159-3861)
- Abdur Rehman (ORCID: https://orcid.org/0000-0003-3785-2007)
- Xiaoyun Cheng (ORCID: https://orcid.org/0000-0002-0115-711X)
- C. Le (ORCID: https://orcid.org/0000-0003-2570-9190)
- Jinsheng Weng (ORCID: https://orcid.org/0000-0003-3668-0143)
- Jing Cao (ORCID: https://orcid.org/0000-0002-8759-6104)
- Chun-Yen Lin (ORCID: https://orcid.org/0000-0003-3007-3190)
- Maya Balakumaran
- Neeraj Saini (ORCID: https://orcid.org/0000-0003-3653-5931)
- Matthew D. Richard (ORCID: https://orcid.org/0009-0009-9477-5619)
- Yongfu Tang (ORCID: https://orcid.org/0000-0002-7916-503X)
- Kamini Singh (ORCID: https://orcid.org/0009-0007-7720-2443)
- Owhofasa Agbedia (ORCID: https://orcid.org/0000-0002-8451-6850)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.64898/2026.11.12.765663
- Primary Topic
- CAR-T cell therapy research
- Type
- preprint
Funders
- U.S. Department of Defense
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute
- Moonshot Research and Development Program